Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
CareDx, Inc
CDNA
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $1.5B
$29.19
▼ -0.21%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$10.96 - $30.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 50.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary dd-cfDNA technology with clinical validation across multiple organ types
- Integrated diagnostic and software platform creating switching costs and patient lock-in
- Strategic partnerships with Illumina for NGS distribution and technology development
- Established relationships with transplant centers and healthcare systems globally
- Comprehensive product portfolio addressing the entire transplant patient journey
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Turning profitable
Expanding adoption of non-invasive dd-cfDNA monitoring in kidney, heart, and lung transplant markets
Value
Fairly valued vs Life Sciences Tools peers
Momentum
Hot
+59.8% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying CDNA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 5, 2026
APR 28, 2026
Reported EPS of $0.34 vs $0.11 consensus (+209.1% surprise). Revenue of $117.7M vs $102.0M expected (+15.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+209.1%
Next: Aug 5, 2026
Revenue trend · last 8Q
—
—
+32%
+18%
-6%
+21%
+25%
+39%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$92.3M
$82.9M
$86.6M
$84.7M
$86.7M
$100.1M
$108.4M
$117.7M
Margins · last 8Q
Gross
—
Operating
—
Profit
2.4%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
$28.00
▼ -4.1% vs $29.19
Latest: BTIG · $28.00 · Apr 29, 2026
1 analyst covering